DataVXACS Materials LettersPaper
journal article·2025-01-06

A General Strategy for Tumor-Specific In Situ Synthesis of Copper Sulfide for Gas Therapy and Surface Plasmon Resonance Enhanced Phototherapy

Wei Cheng, Ying Wu, Bowen Li, Lichao Su, Min Wu, Luntao Liu, Shuhan Wang, Chunhua Lu, Bin Liu

ACS Materials Letters· Volume 7· Issue 1
Publisher page
Source abstract

Abstract

CuS nanomaterials have attracted much attention for tumor therapy because of their excellent photothermal and photodynamic properties. Notably, Cu 2 O can be converted in situ to CuS through sulfurization by H 2 S in tumor cells. However, this approach is currently limited to colon cancer because other tumors exhibit comparatively lower H 2 S concentrations. Herein, we reported a nanoplatform consisting of two key components, diallyl trisulfide (DATS) and Cu 2 O-coated nanogapped gold nanoparticle (AuNNP). DATS reacted with upregulated glutathione (GSH) in tumor cells to release H 2 S for gas therapy as well as the sulfurization of Cu 2 O. AuNNPs further enhanced the photothermal and photodynamic effect of the in situ-formed CuS via surface plasmon resonance effect. Both H 2 S-induced gas therapy and CuS-mediated photothermal/photodynamic therapy exhibited much higher toxicity to tumor cells than to normal cells. Given that GSH is typically overexpressed in cancer cells, the developed strategy is thus generally applicable for almost any tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Quantum Dots Synthesis And Properties · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Joint School of National University of Singapore and Tianjin University

International Campus of Tianjin University

Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore, 117585

MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry

Fuzhou University

Department of Neurosurgery, National Regional Medical Center

Binhai Campus of the First Affiliated Hospital of Fujian Medical University

Fujian Provincial Institutes of Brain Disorders and Brain Sciences

the First Affiliated Hospital of Fujian Medical University

Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine

Chinese Academy of Medical Sciences and Peking Union Medical College

Funding

National University of Singapore · National Natural Science Foundation of China

References (43)

Show source-provided references
1. 10.1038/s41578-023-00589-310.1038/s41578-023-00589-3 ↗
2. 10.1038/s41467-024-46987-110.1038/s41467-024-46987-1 ↗
3. 10.1002/anie.20201644210.1002/anie.202016442 ↗
4. 10.1002/anie.20201735010.1002/anie.202017350 ↗
5. 10.1021/acsnano.2c0358710.1021/acsnano.2c03587 ↗
6. 10.1002/smll.20130117410.1002/smll.201301174 ↗
7. 10.1021/acs.nanolett.7b0416210.1021/acs.nanolett.7b04162 ↗
8. 10.2217/nnm.10.8510.2217/nnm.10.85 ↗
9. 10.1002/smll.20120078310.1002/smll.201200783 ↗
10. 10.1021/ac800847r10.1021/ac800847r ↗
11. 10.7150/thno.1175410.7150/thno.11754 ↗
12. 10.1021/nn506687t10.1021/nn506687t ↗
13. 10.1016/j.actbio.2017.03.00510.1016/j.actbio.2017.03.005 ↗
14. 10.1002/adma.20200464710.1002/adma.202004647 ↗
15. 10.1002/smll.20190347310.1002/smll.201903473 ↗
16. 10.1002/anie.20181008210.1002/anie.201810082 ↗
17. 10.1002/anie.20120770110.1002/anie.201207701 ↗
18. 10.1158/0008-5472.CAN-16-348010.1158/0008-5472.CAN-16-3480 ↗
19. 10.1073/pnas.130624111010.1073/pnas.1306241110 ↗
20. 10.1039/C6SC05646F10.1039/C6SC05646F ↗
21. 10.1021/ja508641z10.1021/ja508641z ↗
22. 10.1002/adma.20150320110.1002/adma.201503201 ↗
23. 10.1021/acsnano.9b0798410.1021/acsnano.9b07984 ↗
24. 10.1002/anie.20211223710.1002/anie.202112237 ↗
25. 10.1038/s41467-023-38601-710.1038/s41467-023-38601-7 ↗
26. 10.1002/advs.20220106910.1002/advs.202201069 ↗
27. 10.1002/advs.20230954210.1002/advs.202309542 ↗
28. 10.1021/acsami.2c1584410.1021/acsami.2c15844 ↗
29. 10.1007/s00441-017-2678-910.1007/s00441-017-2678-9 ↗
30. 10.3390/ijms1808164510.3390/ijms18081645 ↗
31. 10.3892/mmr.2011.65810.3892/mmr.2011.658 ↗
32. 10.3390/ijms14101991110.3390/ijms141019911 ↗
33. 10.1093/abbs/gms03310.1093/abbs/gms033 ↗
34. 10.1016/j.ijpharm.2020.12002010.1016/j.ijpharm.2020.120020 ↗
35. 10.1039/D0NR02543G10.1039/D0NR02543G ↗
36. 10.1016/j.bcp.2017.11.01410.1016/j.bcp.2017.11.014 ↗
37. 10.1002/adma.20180196410.1002/adma.201801964 ↗
38. 10.1016/j.cej.2022.13617010.1016/j.cej.2022.136170 ↗
39. 10.1021/acsami.0c1404610.1021/acsami.0c14046 ↗
40. 10.1002/anie.20220083010.1002/anie.202200830 ↗
41. 10.1038/nrd.2015.110.1038/nrd.2015.1 ↗
42. 10.1021/acs.orglett.5b0196210.1021/acs.orglett.5b01962 ↗
43. 10.1021/acs.nanolett.3c0063210.1021/acs.nanolett.3c00632 ↗